Introduction and objectives: Nonalcoholic fatty liver disease (NAFLD) is the hepatic manifestation of metabolic syndrome. Some dietary fatty acids have showed different bioactive functions in metabolic syndrome. The aim of this study is to determine the dietary consumption patterns and serum percentage of bioactive fatty acids in NAFLD patients. Patients and methods: Cross-sectional study with NAFLD patients and non-NAFLD patients. Dietary consumption of bioactive fatty acids was assessed by a food frequency questionnaire. NAFLD and liver fibrosis were diagnosed by transient elastography. The identification of serum bioactive fatty acids was achieved by gas chromatography–mass spectrometry (%). Bioactive fatty acids consumption was correlat...
Non-alcoholic fatty liver disease (NAFLD) is currently considered the most common liver disease in i...
Metabolic syndrome (MetS) is characterized by interconnected factors related to metabolic disturbanc...
BACKGROUND AND AIM: There is still no approved pharmacotherapy for metabolic (dysfunction) associate...
Non-alcoholic fatty liver disease (NAFLD) ranges from steatosis and hepatic insulin resistance to no...
Background: Free fatty acid (FFA) metabolism can impact on metabolic conditions, such as obesity and...
Non-alcoholic fatty liver disease (NAFLD) is currently the most common cause of liver disease in the...
Changes in lipid metabolism occur during the development and progression non-alcoholic fatty liver d...
Background: Non-alcoholic fatty liver disease (NAFLD) is a wide spectrum condition characterized by ...
International audienceNon-alcoholic fatty liver disease (NAFLD) is considered the most common liver ...
Nonalcoholic fatty liver disease (NAFLD) refers to a wide spectrum of liver damage, ranging from sim...
WPROWADZENIE: NAFLD jest przewlekłą chorobą wątroby, która stanowi istotny problem zdrowotny na cały...
Introduction: Non-alcoholic fatty liver disease (NAFLD) is defined as a worldwide public health prob...
AbstractNonalcoholic fatty liver disease (NAFLD) is the hepatic manifestation of metabolic syndrome ...
Nonalcoholic fatty liver disease (NAFLD) is the hepatic manifestation of metabolic syndrome and a se...
Non-alcoholic fatty liver disease (NAFLD) is currently considered the most common liver disease in i...
Non-alcoholic fatty liver disease (NAFLD) is currently considered the most common liver disease in i...
Metabolic syndrome (MetS) is characterized by interconnected factors related to metabolic disturbanc...
BACKGROUND AND AIM: There is still no approved pharmacotherapy for metabolic (dysfunction) associate...
Non-alcoholic fatty liver disease (NAFLD) ranges from steatosis and hepatic insulin resistance to no...
Background: Free fatty acid (FFA) metabolism can impact on metabolic conditions, such as obesity and...
Non-alcoholic fatty liver disease (NAFLD) is currently the most common cause of liver disease in the...
Changes in lipid metabolism occur during the development and progression non-alcoholic fatty liver d...
Background: Non-alcoholic fatty liver disease (NAFLD) is a wide spectrum condition characterized by ...
International audienceNon-alcoholic fatty liver disease (NAFLD) is considered the most common liver ...
Nonalcoholic fatty liver disease (NAFLD) refers to a wide spectrum of liver damage, ranging from sim...
WPROWADZENIE: NAFLD jest przewlekłą chorobą wątroby, która stanowi istotny problem zdrowotny na cały...
Introduction: Non-alcoholic fatty liver disease (NAFLD) is defined as a worldwide public health prob...
AbstractNonalcoholic fatty liver disease (NAFLD) is the hepatic manifestation of metabolic syndrome ...
Nonalcoholic fatty liver disease (NAFLD) is the hepatic manifestation of metabolic syndrome and a se...
Non-alcoholic fatty liver disease (NAFLD) is currently considered the most common liver disease in i...
Non-alcoholic fatty liver disease (NAFLD) is currently considered the most common liver disease in i...
Metabolic syndrome (MetS) is characterized by interconnected factors related to metabolic disturbanc...
BACKGROUND AND AIM: There is still no approved pharmacotherapy for metabolic (dysfunction) associate...